ARYMO ER

Amid a raging opioid epidemic, Egalet Corp (NASDAQ: EGLT) soared as high as 13 percent Wednesday after the U.S. Food and Drug Administration permitted it to distribute promotional material highlighting the abuse-deterrent properties of intranasal ARYMO ER. The detail is small but notable for Egalet...

The U.S. Food and Drug Administration reached a conclusion this week concerning Endo International plc - Ordinary Shares (NASDAQ: ENDP)'s therapy Opana ER, which is intended to treat pain severe enough to require a daily, around-the-clock, long-term opioid treatment. An independent FDA panel...

Egalet Corp (NASDAQ: EGLT) was surely one of the most watched biotechs of the fourth quarter of 2016. After the company announced the Food and Drug Administration would miss its PDUFA decision date for Egalet’s opioid-based pain medication ARYMO ER, investors waited impatiently for news of a...

After initially spiking as much as 20 percent on Monday following FDA approval of ARYMO ER, shares of Egalet Corp (NASDAQ: EGLT) are down more than 16.4 percent in early Tuesday trading. For traders wondering why Egalet shares are selling off after such good news, the devil is in the details....

Egalet Corp (NASDAQ: EGLT) shares jumped as much as 17 percent on Monday before being halted following news that the FDA has approved ARYMO ER. In its JPMorgan Healthcare Conference presentation, the company said it plans to launch ARYMO ER starting in Q1 2017. The positive news and subsequent halt...

The U.S. Food and Drug Administration approved Egalet Corp (NASDAQ: EGLT)'s ARYMO ER on Monday to expand the industry for opioid-based pain-management treatments. The announcement bodes well for Egalet, the shares of which responded with a 17-percent jump. Trading was halted at 12:24.33 p.m....

Shares of Egalet Corp (NASDAQ: EGLT) traded lower by more than 5 percent Monday morning after a scheduled meeting with the U.S. Food and Drug Administration (FDA) to discuss its delayed ARYMO ER therapy. Egalet said in a press release that the FDA "has identified no particular issue with our...

Egalet Corp (NASDAQ: EGLT) is a U.S.-based specialty pharmaceutical company that focus on treatments for pain and other conditions. The company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. Benzinga had the privilege of chatting with the company...